Razumab Injection injection is classified under Vascular Endothelial Growth Factor antagonist. It is Humanized Monoclonal Antibody designed for intraocular use. Razumab Injection is widely used in the treatment of Wet Age-related Macular degeneration, Diabetec Eye Disease and some times in Retinal Vein occlusion induced Macular Oedema and Diabetic retinopathy. It blocks the abnormal blood vessel growth and it's leakage in the eyes tht may Cause Blurred vision or even vision loss.
Generally Razumab Injection is used to prevent or slow down the Vision loss from Diabetes. It controls the worsening Diabetic Eyes disease condition by curbing abnormal Blood vessels growth that saves a patient from Blindness or Blurred vision. Razumab Injection is administered by Intravitreal injection once every month or at 28days, so Patient Compliance is better compared to other oral formulation used to manage such Eye disease. Razumab Injection has higher binding Affinity towards VEGF-A compared to other Monoclonal Antibodies like Bevacizumab. It has More Retinal penetration and Shorter Sytemic Half-life and lesser Inflammatory side effects.
Razumab Injection is available as a Pre-filled Syringe and Vial form which must be administered by Highly qualified Eye Specialist only as an intravitreal injection. It is available in two strengths: 0.5mg and 0.3mg. Generally Razumab Injection is given once every month but mainly it depends on the condition in which your Eye specialist has prescribed. Your Doctor may Change the Dose, Duration and frequency of the medicine. In ARMD, it may be given for 3-4 months and may get extended as per overall improvement in the condition. After this Frequency of the administration may reduced to once every Three month.
Razumab Injection belongs to VEGF-targeting therapies. T is Humanized Immunoglobulin G1(IgG1) Monoclonal Antibody fragment that act by inhibiting Vascular Endothelial Growth Factor-A, that leads to inhibition of Endothelial Proliferation, Neurovascularization and Vascular Permeability. VEGF-A is a responsible for Vascular leakage and angiogenesis which results into Neovascular age-related macular degeneration (NVAMD) amd other eye related diseases. It is mainly derived from bevacizumab thus higher affinity towards VEGF-A. Being a small sized mAb, it is more compatible and permeable to get diffused in to the retina and choroid.